Showing results (1-10 of 9,618) with videos related to
Sort By:
Pageof 962
Journal of Market Access & Health Policy|March 27, 2025
Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder WorkshopTing Wang, Neil McAuslaneTherapeutic Innovation & Regulatory Science|August 2, 2025
Enhancing Development Strategies Through Early Scientific Advice from HTA Agencies-Experiences, Expectations and Best Practices from Health Technology DevelopersTing Wang, Neil McAuslaneValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder PerceptionsTing Wang, Neil McAuslane, Lawrence Liberti, et al.International Journal of Technology Assessment in Health Care|September 8, 2020
Benchmarking health technology assessment agencies-methodological challenges and recommendationsTing Wang, Iga Lipska, Neil McAuslane, et al.Frontiers in Pharmacology|January 4, 2021
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics StudyTing Wang, Neil McAuslane, Lawrence Liberti, et al.Drug Discovery Today|October 1, 2021
Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agenciesTing Wang, Neil McAuslane, Helga Gardarsdottir, et al.International Journal of Technology Assessment in Health Care|April 11, 2023
Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursementTing Wang, Neil McAuslane, Wim G Goettsch, et al.Frontiers in Pharmacology|August 4, 2022
Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product ProfileTing Wang, Neil McAuslane, Wim G Goettsch, et al.Pharmaceutical Medicine|February 4, 2021
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested SolutionsMagdalena Bujar, Neil McAuslane, Lawrence LibertiClinical Pharmacology and Therapeutics|November 26, 2018
The Confluence of Accelerated Regulatory and Health Technology Assessment Access PathwaysNeil McAuslane, Lawrence Liberti, Patricia ConnellyPageof 962